Yizhi Yu
- Immunology top 1%
- Immunotherapy and Immune Responses 38
- Immune Cell Function and Interaction 20
- Immune Response and Inflammation 17
- T-cell and B-cell Immunology 16
- interferon and immune responses 10
- Immune cells in cancer 9
- Cancer Research top 1%
- Molecular Biology top 2%
- Oncology top 5%
- Chemokine receptors and signaling 8
- Hepatology top 5%
-
- Virus-based gene therapy research 10
- Partner nations
- ChinaCroatiaUnited States
In The Last Decade
Yizhi Yu
92 papers receiving 4.8k citations
Hit Papers
Peers
Comparison fields: 5 of 129
- Immunology 2.3k
- Cancer Research 1.5k
- Molecular Biology 2.6k
- Oncology 838
- Hepatology 179
Countries citing papers authored by Yizhi Yu
This map shows the geographic impact of Yizhi Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yizhi Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yizhi Yu more than expected).
Fields of papers citing papers by Yizhi Yu
This network shows the impact of papers produced by Yizhi Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yizhi Yu. The network helps show where Yizhi Yu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Yizhi Yu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 6 | |
| 2 | The gasdermin family: emerging therapeutic targets in diseasesbreakdown → | 2024 | 45 |
| 3 | 2023 | 4 | |
| 4 | 2022 | 11 | |
| 5 | 2021 | 17 | |
| 6 | 2021 | 23 | |
| 7 | 2020 | 28 | |
| 8 | 2010 | 29 | |
| 9 | 2009 | 34 | |
| 10 | 2009 | 48 | |
| 11 | 2009 | 100 | |
| 12 | 2007 | 14 | |
| 13 | 2005 | 58 | |
| 14 | Intratumoral expression of MIP-1beta induces antitumor responses in a pre-established tumor model through chemoattracting T cells and NK cells. | 2004 | 32 |
| 15 | 2001 | 140 | |
| 16 | 2000 | 90 | |
| 17 | 1998 | 4 | |
| 18 | 1997 | 0 | |
| 19 | 1997 | 1 | |
| 20 | Immunotherapy of cancer by IL-2 gene-transfected tumor vaccine in combination with IL-1, low-dose cyclophosphamide and its immunological mechanisms | 1994 | 0 |
About Yizhi Yu
Yizhi Yu is a scholar working on Immunology, Cancer Research and Oncology, having authored 96 papers that have together received 4.9k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (38 papers), Immune Cell Function and Interaction (20 papers), Immune Response and Inflammation (17 papers), T-cell and B-cell Immunology (16 papers), interferon and immune responses (10 papers), Virus-based gene therapy research (10 papers), Immune cells in cancer (9 papers) and Chemokine receptors and signaling (8 papers). The work is most often cited by research in Immunology (2.3k citations), Cancer Research (1.5k citations) and Molecular Biology (2.6k citations). Yizhi Yu has collaborated with scholars based in China, Croatia and United States. Frequent co-authors include Xuetao Cao, Shuxun Liu, Huazhang An, Jin Hou, Cheng Qian, Yan Gu, Jiangxue Li, Xiaoping Su, Dan Han and Nan Li.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.